Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: A retrospective study

Japanese Journal of Clinical Oncology

Volumn 39, Issue 1, 2009, Pages 43-48

  Seol, Young Mi ^a   Song, Moo Kon ^a   Choi, Young Jin ^a   Kim, Gwang Ha ^b   Shin, Ho Jin ^a   Song, Geun Am ^b   Chung, Joo Seop ^a   Cho, Goon Jae ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

Advanced gastric cancer; Cisplatin; Elderly; Oral fluoropyrimidines

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; FLUOROPYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HAND FOOT SYNDROME; HUMAN; HYPONATREMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR;

EID: 58149383757     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn119     Document Type: Article

References (29)

1. Munoz N, Franceschi S. Epidemiology of gastric cancer and perspectives for prevension. Salud Publica Mex 1997;39:318-30.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalance across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
3. Alberts SR, Cervantes A, van de Velde CJH. Gastric cancer: Epidemiology, pathology and treatment. Ann Oncol 2003;14(Suppl. 2):131-6.
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
5. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
6. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non resectable gastric cancer. Br J Cancer 1995;71:587-91.
7. Cascinu S, Labianca R, Alessandroni P, Marcellini M, Silva RR, Pancera G, et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: A report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997;11:3313-9.
8. Cascinu S, Scartozzi M, Labianca R, Catalano V, Silva RR, Barni S, et al. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: A report from the Italian Group for the Study of Digestive Tract Cancer [GISCAD]. Br J Cancer 2004;8:1521-5.
9. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer a report of the V325 Study Group. J Clin Oncol 2006;24:4991-97.
10. Dank M, Zaluski J, Barone C. Randomised phase III trial of irinotecan+5FU/folinic acid versus CDDP/5FU in 1st-line advanced gastric cancer. J Clin Oncol 2006;23:308.
11. Louvet C, Andre' T, Tigaud JM. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer. J Clin Oncol 2002;20:4543-48.
12. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-7.
13. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-95.
14. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998;34:33-46.
15. Kang Y, Kang WK, Shin DB. Randomized phase III trial of capecitabine/ cisplatin(XP) versus continuous infusion of 5FU/cisplatin (FP) as first-line therapy in patients with advanced gastric cancer: Ef.cacy and safety results. J Clin Oncol 2006;23:4018.
16. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-7.
17. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097-106.
18. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 2002; 38(Suppl.):215-20.
19. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd, Carrato A, et al. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. N Engl J Med 2005;352:2696-704.
20. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, et al. Oral capecitabine as an alternative to i.v.5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003;14:1735-43.
21. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
22. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57.
23. Boku N, Yamamoto S, Shirao K. Randomised phase III study of 5-fluorouracil alone versus combination of irinotecan and cisplatin versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 2007;25:965s (Abstract).
24. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. Randomised controlled trial of S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9:215-21.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
26. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Jr, Albain KS. Under representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.
27. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004;22: 4626-31.
28. Tsuji A, Shima Y, Morita S, Uchida M, Okamoto K, Morita M, et al. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: A retrospective study. Anticancer Res 2008;28:1433-8.
29. Kang Y, Lee J, Min Y. A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. J Clin Oncol 2007;25:18S (Abstract 4546).